Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 1/2014

01.02.2014

Targeting Interleukin-22 in Psoriasis

verfasst von: Ji-Qing Hao

Erschienen in: Inflammation | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-22 (IL-22) is an IL-10 family cytokine that was recently discovered to be released by T helper 17 (Th17) cells, Th22 cells, etc. Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of psoriasis. For instance, IL-22 can inhibit keratinocyte terminal differentiation and can induce psoriasis-like epidermis alterations; serum IL-22 levels were correlated with the disease severity of psoriasis patients, and IL-22 mRNA was positively expressed in the psoriatic skin lesions, but negatively expressed in the normal controls. All these findings suggest that IL-22 may be implicated in psoriasis; therapeutics targeting IL-22 may have promise as a potential therapeutic target for treating psoriasis. In the present review, we summarize recent advances on the role of IL-22 in the pathogenesis and treatment of psoriasis.
Literatur
1.
Nestle, F.O., D.H. Kaplan, and J. Barker. 2009. Psoriasis. New England Journal of Medicine 361: 496–509.CrossRefPubMed
2.
3.
Pan, H.F., R.X. Leng, C.C. Feng, et al. 2013. Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. Molecular Biology Reports 40: 391–399.PubMedCrossRef
4.
Zhao, X.F., H.F. Pan, H. Yuan, et al. 2010. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Molecular Biology Reports 37: 81–85.PubMedCrossRef
5.
Chung, Y., X. Yang, S.H. Chang, et al. 2006. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Research 16: 902–907.PubMedCrossRef
6.
Liang, S.C., X.Y. Tan, D.P. Luxenberg, et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. Journal of Experimental Medicine 203: 2271–2279.CrossRefPubMedPubMedCentral
7.
Duhen, T., R. Geiger, D. Jarrossay, et al. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nature Immunology 10: 857–863.PubMedCrossRef
8.
Trifari, S., C.D. Kaplan, E.H. Tran, et al. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nature Immunology 10: 864–871.PubMedCrossRef
9.
Pan, H.F., X.P. Li, S.G. Zheng, et al. 2012. Emerging role of interleukin-22 in autoimmune diseases. Cytokine & Growth Factor Reviews 24: 51–57.CrossRef
10.
Wolk, K., E. Witte, K. Warszawska, et al. 2009. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. European Journal of Immunology 39: 3570–3581.PubMedCrossRef
11.
Liu, H., K. Huang, Y. Wu, et al. 2007. The expression of interleukin-22 and S100A7, A8, A9 mRNA in patients with psoriasis vulgaris. Journal of Huazhong University of Science and Technology. Medical Sciences 27: 605–607.CrossRef
12.
Ouyang, W. 2010. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine & Growth Factor Reviews 21: 435–441.CrossRef
13.
Sabat, R. 2010. IL-10 family of cytokines. Cytokine & Growth Factor Reviews 21: 315–324.CrossRef
14.
Wolk, K., and R. Sabat. 2006. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine & Growth Factor Reviews 17: 367–380.CrossRef
15.
Wolk, K., S. Kunz, E. Witte, et al. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241–254.PubMedCrossRef
16.
Fujita, H., K.E. Nograles, T. Kikuchi, et al. 2009. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proceedings of the National Academy of Sciences of the United States of America 106: 21795–21800.PubMedPubMedCentralCrossRef
17.
Zhang, N., Pan, H. F. & Ye, D. Q. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 353, 41–6
18.
Simonian, P. L., Wehrmann, F., Roark, C. L., et al. γδ T cells protect against lung fibrosis via IL-22. J Exp Med 207, 2239–53.
19.
Cella, M., A. Fuchs, W. Vermi, et al. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457: 722–725.PubMedCrossRef
20.
Guo, H. & Topham, D. J. Interleukin-22 (IL-22) production by pulmonary natural killer cells and the potential role of IL-22 during primary influenza virus infection. J Virol 84, 7750–9.
21.
Zenewicz, L. A. & Flavell, R. A. Recent advances in IL-22 biology. Int Immunol 23, 159–63.
22.
Cupedo, T., N.K. Crellin, N. Papazian, et al. 2009. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nature Immunology 10: 66–74.PubMedCrossRef
23.
Takatori, H., Y. Kanno, W.T. Watford, et al. 2009. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. Journal of Experimental Medicine 206: 35–41.CrossRefPubMedPubMedCentral
24.
Lejeune, D., L. Dumoutier, S. Constantinescu, et al. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. Journal of Biological Chemistry 277: 33676–33682.CrossRefPubMed
25.
Dumoutier, L., J. Louahed, and J.C. Renauld. 2000. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. Journal of Immunology 164: 1814–1819.CrossRef
26.
Zheng, Y., D.M. Danilenko, P. Valdez, et al. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648–651.PubMedCrossRef
27.
Tagoe, C., and C. Putterman. 2012. JAK2 inhibition in murine systemic lupus erythematosus. Immunotherapy 4: 369–372.PubMedCrossRef
28.
Jia, Y., J. Jing, Y. Bai, et al. 2011. Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-kappaB signaling pathways. PLoS One 6: e27006.PubMedPubMedCentralCrossRef
29.
Jiang, Z., H. Li, D.C. Fitzgerald, et al. 2009. MOG(35–55) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. European Journal of Immunology 39: 789–799.PubMedPubMedCentralCrossRef
30.
Arumugam, S., R.A. Thandavarayan, P.T. Veeraveedu, et al. 2012. Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant. Experimental and Molecular Pathology 93: 183–189.PubMedCrossRef
31.
Noubade, R., D.N. Krementsov, R. Del Rio, et al. 2011. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118: 3290–3300.PubMedPubMedCentralCrossRef
32.
Mitra, A., R.S. Fallen, and H.C. Lima. 2012. Cytokine-based therapy in psoriasis. Clinical Reviews in Allergy & Immunology 44: 173–182.CrossRef
33.
Nograles, K.E., L.C. Zaba, E. Guttman-Yassky, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. British Journal of Dermatology 159: 1092–1102.PubMed
34.
Pan, H.F., X.F. Zhao, H. Yuan, et al. 2009. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clinica Chimica Acta 401: 179–180.CrossRef
35.
Qin, W.Z., L.L. Chen, H.F. Pan, et al. 2011. Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clinical and Experimental Medicine 11: 245–250.PubMedCrossRef
36.
Lavoie, T.N., C.M. Stewart, K.M. Berg, et al. 2011. Expression of interleukin-22 in Sjogren's syndrome: significant correlation with disease parameters. Scandinavian Journal of Immunology 74: 377–382.PubMedPubMedCentralCrossRef
37.
Caproni, M., E. Antiga, L. Melani, et al. 2009. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. Journal of Clinical Immunology 29: 210–214.PubMedCrossRef
38.
Lo, Y.H., K. Torii, C. Saito, et al. 2010. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. Journal of Dermatological Science 58: 225–227.PubMedCrossRef
39.
Nakajima, H., K. Nakajima, M. Tarutani, et al. 2011. Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Archives of Dermatological Research 303: 451–455.PubMedPubMedCentralCrossRef
40.
Meephansan, J., K. Ruchusatsawat, W. Sindhupak, et al. 2011. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. European Journal of Dermatology 21: 501–504.PubMedCrossRef
41.
Sabat, R., and K. Wolk. 2011. Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. Journal der Deutschen Dermatologischen Gesellschaft 9: 518–523.PubMed
42.
Wolk, K., H.S. Haugen, W. Xu, et al. 2009. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 87: 523–536.CrossRef
43.
Boniface, K., F.X. Bernard, M. Garcia, et al. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. Journal of Immunology 174: 3695–3702.CrossRef
44.
Van Belle, A.B., M. de Heusch, M.M. Lemaire, et al. 2012. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. Journal of Immunology 188: 462–469.CrossRef
45.
Pantelyushin, S., S. Haak, B. Ingold, et al. 2012. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. Journal of Clinical Investigation 122: 2252–2256.CrossRefPubMedPubMedCentral
46.
Ma, H.L., S. Liang, J. Li, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. Journal of Clinical Investigation 118: 597–607.PubMedPubMedCentral
47.
Krueger, J.G. 2012. Hiding under the skin: a welcome surprise in psoriasis. Nature Medicine 18: 1750–1751.PubMedCrossRef
Metadaten
Titel
Targeting Interleukin-22 in Psoriasis
verfasst von
Ji-Qing Hao
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9715-y

Weitere Artikel der Ausgabe 1/2014

Inflammation 1/2014 Zur Ausgabe

OriginalPaper

MiR-146a Regulates IL-6 Production in Lipopolysaccharide-Induced RAW264.7 Macrophage Cells by Inhibiting Notch1

OriginalPaper

Thymol Inhibits LPS-Stimulated Inflammatory Response via Down-Regulation of NF-κB and MAPK Signaling Pathways in Mouse Mammary Epithelial Cells

Erratum

Erratum to: Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain

OriginalPaper

Hyperleptinemia: Implications on the Inflammatory State and Vascular Protection in Obese Adolescents Submitted to an Interdisciplinary Therapy

OriginalPaper

Activin A: A Potential Therapeutic Target for Characterizing and Stopping Joint Pain Early in Rheumatoid Arthritis Patients

OriginalPaper

High Asymmetric Dimethylarginine (ADMA) Levels in Patients with Brucellosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise